{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"59.000","floor":"48.500"},"ipodate":{"start":"2015-04-20 00:00:00","end":"2015-04-23 00:00:00"},"minimumcapital":"5959.00","subscribed":"179.36","marketcap":"94.40億","H_marketcap":"23.60億","pe":"41.07","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/06826/LTN20150420058_C.pdf","ipopricing":"59.000","resultdate":"2015-04-29 00:00:00","enddate":"2015-04-23 00:00:00","listeddate":"2015-04-30 00:00:00","issuenumber":"4000.00萬","issuenumberhK":"400.00萬","issuenumberother":"3600.00萬","grayprice":"56.25","sponsors":"瑞銀證券香港有限公司","raisemoney":"225200.00萬","use":"1、約25%或約563百萬港元，將用于建設上海利康瑞的新生產線，包括動物源纖維蛋白封閉劑產品及醫用生物材料的新生產設施，以應付對產品不斷增長的需求；\n2、約25%或約563百萬港元，將用于選擇性收購專注于我們目標治療領域內具高增長潛能產品及對我們現有產品組合具互補性產品的合適生物醫藥或醫用生物材料公司或資產。截至最后實際可行日期，我們尚未物色到任何可予收購的目標；\n3、約18%的所得款項凈額，或約405百萬港元，將用于購買新生產設備，以及翻新及改造昊海生物設施；\n4、約13%或約293百萬港元，將用于資助在研產品（包括溫敏性幾丁糖產品及新一代交聯透明質酸鈉產品）的研發活動及臨床應用；\n5、約9%或約203百萬港元，將用于招聘更多營銷及銷售人員以擴大我們的銷售及營銷網絡，及將我們成功開發的在研產品進行商業投產，以及提升營銷及促銷活動水平；\n6、約10%或約225百萬港元，將用作營運資金及一般企業用途。","shares":100,"leadagent":"瑞士銀行香港分行,招銀國際融資有限公司,建銀國際金融有限公司","bookrunners":"瑞士銀行香港分行,招銀國際融資有限公司,建銀國際金融有限公司","coordinator":"瑞士銀行香港分行","firstDayOpen":"54.00","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"瑞士銀行香港分行","code":"E06826","name":"昊海生物科技","fullname":"上海昊海生物科技股份有限公司"},"institutioninfo":{"principaloffice":"中國上海長寧虹橋路1386號文廣大廈23樓 ","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"侯永泰","secretary":"田敏,趙明璟","telephone":"(021) 5229 3555 ","substantialshareholders":"蔣偉(50.65%),樓國梁(6.25%)","principalactivities":"公司業務包括生物制劑及醫用透明質酸的生產及銷售、生物工程及醫藥產品研發以及提供相關服務。","website":"http://www.3healthcare.com/"},"managerinfo":[],"investorinfo":[{"institutionname":"方圓投資管理(香港)有限公司","shareholding":"3,940,000.0","percentage":2.46,"ReleaseDate":"2015-10-30 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Dragon Billion China Master Fund","shareholding":"3,283,000.0","percentage":2.05,"ReleaseDate":"2015-10-30 00:00:00","relatedparty":"涌金資產管理有限公司","subsidiary":["Prime Capital Funds","Dragon Billion China Master Fund"],"InverstorType":"基金"}],"TotalShareholdingPercentage":4.51},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":514}